Find Solutions

What professional support are you looking for?

Describe your professional need to reach the right professionals and services worldwide

Please sign in to continue
Support
Login
  1. Insights/
  2. Tigermed-Jyton supports China NMPA Approval of Retoxin® ——The World’s First Clinical Trial on Therapeutic Indication of Recombinant Botulinum Toxin Type A
Article

Tigermed-Jyton supports China NMPA Approval of Retoxin® ——The World’s First Clinical Trial on Therapeutic Indication of Recombinant Botulinum Toxin Type A

ContactContact Consultant
Consultants
Beijing Tigermed-Jyton Co., LTD.
Beijing Tigermed-Jyton Co., LTD.Beijing Tigermed-Jyton Co., Ltd. offers "one-stop services" for clinical trials, including project management, clinical monitoring, pharmacovigilance, medical monitoring, data management, statistical analysis, medical writing, and SMO services. This "one-stop" approach ensures higher quality, lower costs, and shorter project timelines, helping sponsors bring their products to market faster.
Categories
01China
02Business Services
03Consulting Services
04Life Sciences

Apr 2, 2026
Beijing Tigermed-Jyton Co., LTD.
Tigermed-Jyton supports China NMPA Approval of Retoxin® ——The World’s First Clinical Trial on Therapeutic Indication of Recombinant Botulinum Toxin Type A
Privacy Policy
Rules Center
Linkedin

Leadvisor Platform © 2020-2026